{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:40:32Z","timestamp":1790484032314,"version":"4.1.0"},"reference-count":31,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Purpose: To investigate the response to gabapentin treatment in patients with dry eye (DE) accompanied by features of neuropathic ocular pain (NOP), and to analyze the differences between clinical manifestations of the groups according to treatment response. Methods: We retrospectively reviewed the records of 35 patients with DE accompanied by NOP features and obtained information on their medical history and previous ocular history. The patients underwent clinical examinations of the tear film, ocular surface, and meibomian gland and completed the Ocular Pain Assessment Survey (OPAS). One month after treatment with topical eye drops, add-on of gabapentin treatment was determined according to the Wong\u2013Baker FACES Pain Rating Scale (WBFPS). A reduction of 2 points or more on the WBFPS was considered a positive treatment response. Enrolled patients were divided into three groups according to the treatment response: topical treatment response group (group 1, n = 11); gabapentin response group (group 2, n = 13); and gabapentin non-response group (group 3, n = 11). The medical history, clinical parameters, and OPAS scores were compared between groups. Results: The incidence of systemic comorbidities was higher in group 2 than in other groups. The corneal staining scores were lower in groups 2 and 3 than in group 1. Among the treatment response groups, group 2 showed improvements in OPAS scores of ocular pain severity, pain other than eyes, and quality of life, while group 1 showed improved OPAS scores of ocular pain severity and ocular associated factors. Group 2 exhibited lower scores of pains aggravated by mechanical and chemical stimuli than group 3. Conclusions: Gabapentin could be effective in patients who have systemic comorbidity and less pain evoked by mechanical and chemical stimuli for the treatment of DE patients with NOP, which is refractory to topical treatment.<\/jats:p>","DOI":"10.3390\/jcm9113765","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T11:50:34Z","timestamp":1606132234000},"page":"3765","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment Response to Gabapentin in Neuropathic Ocular Pain Associated with Dry Eye"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8790-7021","authenticated-orcid":false,"given":"Hyeon-Jeong","family":"Yoon","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-9835","authenticated-orcid":false,"given":"Jonghwa","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2788-1851","authenticated-orcid":false,"given":"Kyung Chul","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification Report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_4","first-page":"7","article-title":"Differential Diagnosis: Nociceptive and Neuropathic Pain","volume":"12","author":"Nicholson","year":"2006","journal-title":"Am. J. Manag. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-020-01282-3","article-title":"A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain","volume":"80","author":"Dermer","year":"2020","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Small, L.R., Galor, A., Felix, E.R., Horn, D.B., Levitt, R.C., and Sarantopoulos, C.D. (2019). Oral Gabapentinoids and Nerve Blocks for the Treatment of Chronic Ocular Pain. Eye Contact Lens.","DOI":"10.1097\/ICL.0000000000000630"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/eye.2014.263","article-title":"Neuropathic ocular pain: An important yet underevaluated feature of dry eye","volume":"29","author":"Galor","year":"2015","journal-title":"Eye"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.ophtha.2017.08.004","article-title":"Neuropathic Corneal Pain","volume":"124","author":"Dieckmann","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_11","first-page":"746","article-title":"Burning Eye Syndrome: Do Neuropathic Pain Mechanisms Underlie Chronic Dry Eye?","volume":"17","author":"Kalangara","year":"2016","journal-title":"Pain Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1126\/science.aaf8933","article-title":"Neural circuits for pain: Recent advances and current views","volume":"354","author":"Peirs","year":"2016","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtos.2017.10.001","article-title":"Neuropathic pain and dry eye","volume":"16","author":"Galor","year":"2018","journal-title":"Ocul. Surf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1113-e88","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"European Federation of Neurological Societies EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12272-013-0057-y","article-title":"Implications and mechanism of action of gabapentin in neuropathic pain","volume":"36","author":"Kukkar","year":"2013","journal-title":"Arch. Pharmacal. Res."},{"key":"ref_16","first-page":"5","article-title":"Gabapentin reverses central pain sensitization following a collagenase-induced intrathalamic hemorrhage in rats","volume":"7","author":"Castel","year":"2013","journal-title":"J. Pain Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00000542-200412000-00021","article-title":"Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia","volume":"101","author":"Gottrup","year":"2004","journal-title":"Anesthesiology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Michael, R., Jeffers, J.V., Messenger, W., and Aref, A.A. (2020). Gabapentin for presumed neuropathic ocular pain. Am. J. Ophthalmol. Case Rep., 19.","DOI":"10.1016\/j.ajoc.2020.100836"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ongun, N., and Ongun, G.T. (2019). Is gabapentin effective in dry eye disease and neuropathic ocular pain?. Acta Neurol. Belg.","DOI":"10.1007\/s13760-019-01156-w"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.survophthal.2012.11.004","article-title":"Management of post-photorefractive keratectomy pain","volume":"58","author":"Woreta","year":"2013","journal-title":"Surv. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archopht.121.11.1537","article-title":"A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability","volume":"121","author":"Miyata","year":"2003","journal-title":"Arch Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","article-title":"The international workshop on meibomian gland dysfunction: Report of the diagnosis subcommittee","volume":"52","author":"Tomlinson","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_24","unstructured":"(2020, October 20). Wong-Baker FACES Foundation. Available online: https:\/\/wongbakerfaces.org\/."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.ophtha.2016.03.006","article-title":"Validity and Reliability of a Novel Ocular Pain Assessment Survey in Quantification and Monitoring of Corneal and Ocular Surface Pain","volume":"123","author":"Qazi","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.pain.2008.04.025","article-title":"The Kyoto protocol of IASP Basic Pain Terminology","volume":"137","author":"Loeser","year":"2008","journal-title":"Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.5301\/ejo.5000143","article-title":"Pregabalin and gabapentin for post-photorefractive keratectomy pain: A randomized controlled trial","volume":"22","author":"Pakravan","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Galor, A., Patel, S., Small, L.R., Rodriguez, A., Venincasa, M.J., Valido, S.E., Feuer, W., Levitt, R.C., Sarantopoulos, C.D., and Felix, E.R. (2019). Pregabalin Failed to Prevent Dry Eye Symptoms after Laser-Assisted in Situ Keratomileusis (LASIK) in a Randomized Pilot Study. JCM, 8.","DOI":"10.3390\/jcm8091355"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","article-title":"Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial","volume":"280","author":"Rowbotham","year":"1998","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1474-4422(14)70102-4","article-title":"Allodynia and hyperalgesia in neuropathic pain: Clinical manifestations and mechanisms","volume":"13","author":"Jensen","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jpain.2008.05.014","article-title":"Pregabalin for postherpetic neuralgia: Placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief","volume":"9","author":"Stacey","year":"2008","journal-title":"J. Pain"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3765\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:35:43Z","timestamp":1760178943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["jcm9113765"],"URL":"https:\/\/doi.org\/10.3390\/jcm9113765","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,22]]}}}